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Summary
Background—Cognitive decline is a debilitating manifestation of disease progression in 
Parkinson’s disease. We aimed to develop a clinical-genetic score to predict global cognitive 
impairment in patients with the disease.
Methods—A prediction algorithm for global cognitive impairment (defined as Mini Mental State 
Exam (MMSE) ≤25) was built using data from 1,350 patients with 5,165 longitudinal visits over 
12.8 (median, 2.8) years. Age at onset, MMSE, education, motor exam score, gender, depression 
and GBA mutations, machine selected through stepwise Cox’ hazards analysis and Akaike’s 
information criterion, were used to compute the multivariable predictor. Independent validation 
was achieved in another 1,132 patients with 19,127 visits over 8.6 (median, 6.5) years.
Findings—The cognitive risk score accurately predicted cognitive impairment within ten years 
of disease onset with an area under the curve (AUC) of >0.85 in both the discovery (95% CI, 
0.821–0.902) and validation populations (95% CI, 0.779 – 0.913). 72.6% of patients scoring in the 
highest quartile were cognitively impaired by ten years vs. 3.7% in the lowest quartile (hazard 
ratio, 18.4, 95% CI, 9.4 – 36.1). Dementia or disabling cognitive impairment was predicted with 
an AUC of 0.877 (95% CI 0.788–0.943) and high negative predictive value (0.920, 95% 0.877–
0.954) at the predefined cutoff (0.196). Performance was stable in 10,000 randomly resampled 
subsets.
Interpretation—Our predictive algorithm provides a potential test for future cognitive health or 
impairment in patients with Parkinson’s. It could improve trials of cognitive interventions and 
inform on prognosis.
Introduction
Cognitive decline is one of the most debilitating manifestations of disease progression in 
Parkinson’s and a key determinant of a patient’s quality of life and independence1. The 
ability to predict and manage this complication is highly relevant for recruitment and 
stratification of clinical trials, particularly those designed to slow disease progression and to 
prevent dementia. While a multitude of Parkinson’s medications is available to improve 
motor aspects of the disease, these do not have a major effect on cognitive decline.
Demographic and clinical risk factors for cognitive decline in PD are emerging. Age-at-
onset2,3, depression2, and education2 have been nominated as predictors of dementia in 
multiple small or medium-sized cohorts (e.g. the largest published study examined 400 
subjects for several years)2,3. Measures of baseline disease severity using motor and 
cognitive scores are linked to an increased risk of developing future dementia2,3. 
Complementing these clinical clues, mutations in the β-glucocerebrosidase gene (GBA; 
found in about 10% of patients with gene sequencing) are linked to accelerated cognitive 
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decline in PD4,5. Other progression loci have been nominated, but remain controversial or 
await further replication in large, longitudinal studies (e.g. APOE, SNCA, MAPT; reviewed 
in Ref.6).
Here we develop a clinical-genetic score predictive of global cognitive impairment in a 
discovery set of 1,350 participants with PD followed in six longitudinal cohorts and 
validated in 1,132 participants from three independent longitudinal cohorts. The versatile 
cognitive risk calculator for PD (http://scherzerlaboratory.org/tools/login.php) can be used to 
calculate a patient’s risk estimate.
Methods
Study Design and Participants
Figure 1 shows a summary of our workflow. Table 1 describes the cohorts. Details are 
available in the appendix. 3,200 patients with PD were longitudinally assessed with 27,022 
study visits in nine cohorts2,7–13 from North America and Europe between 1986 and 2016 
(table 1 and appendix figure 1). 96.3% of study visits occurred within 12 years of follow-up 
with a median follow-up time of 6.4 years from disease onset (inter-quartile range, 4.6 years) 
(appendix figure 2). We thus focused our primary analysis on the 12-year time frame from 
disease onset. Serial Mini Mental State Exam (MMSE) scores14 were longitudinally 
collected in seven cohorts. Montreal Cognitive Assessment (MoCA)15 scores were collected 
in two cohorts and converted to MMSE scores according to a published formula16. To ensure 
consistency across studies, an MMSE score with the cutoff of ≤ 25 was defined as an 
indicator of significant global cognitive impairment as recommended by the International 
Parkinson and Movement Disorders Society (MDS) Task Force17. Cohort-specific 
definitions of Parkinson’s disease dementia were used (appendix table 1). The MDS-Unified 
PD Rating Scale (UPDRS) part II and III scores were obtained from four cohorts, and 
estimated for the five remaining cohorts using the UPDRS or SPES/SCOPA-motor scales18 
based on published conversion formulas19,20 (table 1). Hoehn and Yahr scales (HY)14 were 
longitudinally collected in all cohorts. Ethnicity was self-reported. GBA mutations were 
retrospectively genotyped and defined as in Ref.4. For several cohorts this analysis evaluated 
previously collected longitudinal phenotypic data; for the active HBS, PPMI, PDBP, DIGPD 
cohorts both retro- and prospectively collected longitudinal data elements were included. 
Because stratification of patients in clinical trials is a potential application of the prognosis 
score, we a priori assigned the two trial cohorts, DATATOP and PreCEPT, together with 
PPMI to the validation population (figure 1). Written informed consent for each cohort was 
obtained from the participants under the supervision of each local ethics committee. The 
Institutional Review Board of Partners HealthCare approved the current analyses.
Statistical Analysis
Building the Cognitive Risk Score
The discovery population was used to evaluate candidate clinical and GBA risk factors and 
to build the predictive score using a statistic similar to the Framingham Cardiovascular Risk 
score21. A step by step calculation of the score is included in the appendix table 4, figure 6. 
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Nine clinical and genetic risk factors previously associated with dementia in PD were 
considered for evaluation based on prior evidence2,3 and applicability to our datasets: GBA 
mutation status, age at onset of PD, gender, years of education at baseline, baseline MMSE, 
MDS-UPDRS II, MDS-UPDRS III scores, Hoehn & Yahr stage, and baseline depression 
status. GBA was included because of unequivocal evidence from multiple, large longitudinal 
studies (e.g.4,5). Other candidate progression loci are controversial and need further 
longitudinal replication6. The Cox proportional hazards statistic was used to estimate the 
influence of these risk factors on time (years from PD onset) to reaching the endpoint of 
global cognitive impairment (i.e., duration of diagnosed PD illness at point of cognitive 
impairment) during longitudinal follow-up in the discovery population. The Cox regression 
coefficients, which were incorporated into the cognitive predictive score, each index the 
hazard rate throughout the time period analyzed, which is assumed to be constant throughout 
that period. This “proportional hazard assumption” was valid for all predictors except the 
MDS-UPDRS II, which was discarded for this reason. The eight remaining risk factors were 
entered into a multivariable Cox model. Backward elimination was performed to remove 
uninformative variables from the model based on the lowest Akaike’s information criterion 
(AIC). Hoehn & Yahr stage was eliminated from the model during this process (AIC of 
2,088.2 without HY vs. 2,089.5 with HY). The final multivariable Cox regression model 
then included the remaining seven risk factors (figure 1). To adjust for differences among the 
seven cohorts, a “cohort” term was included as a random effect (using a “frailty” Cox 
model). The score was then validated in 1,132 patients with 19,127 follow-up visits over 8.6 
(median, 6.5; IQR 3.1) years. Cochran’s Q-test and the I2 index were used to test for 
heterogeneity across studies (appendix table 2). In all analyses, p values less than or equal to 
0.05 were considered statistically significant.
Application to Dementia
Dementia is characterized as a loss of cognitive ability severe enough to interfere with 
normal activities of daily living17. We conservatively tested dementia prediction in 
individuals with PD (without cognitive impairment at enrollment) in the validation 
population that was not used to build the predictive score. 1,132 patients with 19,127 
longitudinal study visits were available for this analysis.
Stability
To test the stability of the predictive score we rebuilt and retested the score in 10,000 
training and test sets randomly generated from the entire study population.
Generalized Mixed Random and Fixed Effects Longitudinal Meta-analysis (LMM)
To evaluate longitudinal trajectories of serial MMSE and MoCA scores in patients with high 
(> 0.196) vs. low cognitive predictive scores (≤ 0.196) at enrollment, we performed LMM 
adjusting for disease duration at enrollment using appropriate cohorts from the validation 
population.
Detailed methods, statistical analyses, supplemental results, and illustrative case studies are 
shown in the appendix.
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The Online Calculator can be found at http://scherzerlaboratory.org/tools/login.php
Role of the funding source—The study funders had no role in the study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding 
author and all coauthors had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Clinical-genetic score and prediction of cognitive decline in the discovery population
3,200 patients with PD from nine cohorts were screened for eligibility. 235 patients were 
excluded because of a MMSE ≤ 25 at baseline; 135 were excluded because their first study 
visit occurred more than 12 years from disease onset. Six cohorts representing 1,350 patients 
(after exclusion of an additional 334 patients with missing covariates) with 5,165 
longitudinal visits over 12.8 (median, 2.8; interquartile range (IQR) 3.1) years) were 
assigned to the discovery population (figure 1): HBS, CamPaIGN, PICNICS, PROPARK, 
DIGPD and PDBP. The proportional variance in the cognitive predictive scores accounted 
for by the model as a whole was 97.4%. Each of the seven predictors included into the 
model significantly contributed to the information content of the score. Age at PD onset was 
responsible for 56.5% of the variance, followed by MMSE at enrollment (7.7%), years of 
education (5.4%), MDS-UPDRS part III score at enrollment (4.7%), gender (2.6%), 
depression at enrollment (1.9%), and GBA carrier status (1.5%).
Our cognitive risk score showed high accuracy (quantified by AUC estimates) for predicting, 
whether a patient will develop global cognitive impairment within ten years from disease 
onset. In the discovery population, the AUC was 0.863 (95% CI 0.821–0.901; figure 2A); 
with a specificity of 0.717 (95%CI 0.652–0.775) and a sensitivity of 0.865 (95%CI 0.802–
0.918) at the optimal cutoff (0.196). Patients with cognitive predictive scores in the highest 
(fourth) quartile had a dramatically increased hazard ratio (HR) for global cognitive 
impairment of 21.6 (95% CI, 10.9 – 42.9) compared to those in the lowest risk quartile (the 
reference quartile; p < 0.0001, table 2). Kaplan-Meier survival curves of subjects in the 
highest and lowest risk quartiles, respectively (figure 2C), revealed that 95.8% (95% CI 
92.7%–99.1%) of patients in the lowest quartile of predictive scores survived for ten years 
without global cognitive impairment in contrast to only 34.9% (95% CI 26.5%–46.2%) in 
the highest quartile (a 60.9% difference; p < 0.0001 log-rank test; figure 2C).
Prediction of cognitive decline in the validation population
The score built in the discovery study (consisting of the seven predictors and β coefficients 
from the discovery study) was locked-in and applied “as is” to the new patients. Similarly, 
the quartile ranges and the optimal cutoff identified in the discovery study were rigorously 
applied to the validation population. The predictive score was accurate in the validation 
population with an AUC of 0.854 (95% CI 0.779–0.913) (figure 2B). Specificity was 0.744 
(95% CI 0.604–0.868) and sensitivity was 0.733 (95% CI 0.617–0.831) at the pre-set cutoff 
of a score of 0.196. Adjusting for a 26.7% prevalence of Mild Cognitive Impairment in non-
demented patients with PD patients22 yielded a negative predictive value of 0.884 (95% CI 
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0.818–0.923) with a positive predictive value of 0.510 (95% CI 0.400–0.639). Patients with 
predictive scores in the highest (fourth) quartile had a substantially increased HR for global 
cognitive impairment of 18.4 (95% CI, 9.4 – 36.1) compared to those in the lowest risk 
quartile (table 2). Kaplan-Meier survival curves of subjects in the highest and lowest quartile 
of predictive scores, respectively, in the validation population are shown in figure 2D. 96.3% 
(95% CI 94.1% – 98.6%) of patients in the lowest quartile of predictive scores survived for 
ten years without global cognitive impairment while only 27.4% (95% CI 12.6%–59.8%) of 
patients in the highest quartile of predictive scores survived for ten years without global 
cognitive impairment in the validation population (a 68.9% difference; p < 0.0001 log-rank 
test; figure 2D).
Prediction of dementia
Cohort-specific definitions of a clinical diagnosis of PD dementia (PDD) were employed as 
described in the Methods. The AUC for predicting dementia within ten years from onset was 
0.877 (95% CI 0.788–0.943) — even higher than for global cognitive decline (figure 3). At 
the cutoff of 0.196, dementia was predicted with a sensitivity of 0.861 (95% CI 0.716–
0.944) and specificity of 0.721 (95% CI 0.594–0.841). The negative predictive values for 
dementia ranged from 0.920 (95% 0.877–0.954) to 0.941 (95% CI 0.919 – 0.961) based on 
systematic estimates of prevalence of dementia amongst patients with PD ranging from 
31.1% (high quality studies)23 to 24.5% (all studies)23. Patients with predictive scores in the 
highest (fourth) quartile had a substantially increased HR for dementia of 21.9 (95% CI, 6.5 
– 73.1) compared to those scoring in the lowest quartile (table 3). 98.9 (95% CI 97.6% – 
99.9%) of patients in the lowest quartile of predictive scores survived for ten years without 
dementia while only 48.3% (95% CI 21.3%–62.8%) of patients in the highest quartile of 
predictive scores survived for ten years without dementia (a 50.6% difference; p < 0.0001 
log-rank test).
Stable predictive accuracy in 10,000 re-sampled training and test sets
In 10,000 iterations, age at onset, enrollment MMSE score, and years of education remained 
in the model after stepwise pruning in 100% of iterations, enrollment MDS-UPDRS III in 
98.30%, GBA carrier status in 91.79%, depression in 90.61%, and gender in 78.52% (figure 
4A). HY stage (which did not make it into our clinical-genetic score) was added to the 
model in 34.86% of iterations. Across 10,000 re-sampled test sets, the mean AUC was 0.833 
(95% CI, 0.785–0.876) consistent with stable performance. Moreover, the score stably and 
accurately predicted dementia across the 10,000 re-sampled training and test sets with an 
average training AUC of 0.879 (95% CI 0.837–0.916) and an average testing AUC of 0.872 
(95% CI 0.817–0.920) (figure 4B).
Prediction of longitudinal trajectories in MoCA scores
PD patients with high enrollment predictive scores had a significantly more rapid 
longitudinal decline in MMSE scores over time with p < 0.0001 compared to the patients 
with low enrollment predictive scores (figure 5A). The MoCA test may be more sensitive 
than the MMSE for detecting cognitive change in patients with PD15. We analyzed the 
longitudinal trajectories of MoCA scores in PPMI and PreCEPT, two of the validation 
cohorts, which have included this scale into their assessment battery. Patients with high 
Liu et al. Page 6













predictive scores at enrollment had a much steeper decline in MoCA scores over time 
compared to patients with low predictive scores with p < 0.0001 (figure 5B).
Improving power in a hypothetical clinical trial
We performed a power analysis to estimate sample size requirements for a three-year clinical 
trial of a hypothetical drug designed to halt cognitive decline (as measured by serial MoCA 
or MMSE, respectively) in a trial of patients predicted to be at high risk of cognitive decline 
based on an enrollment cognitive risk scores at or above the cutoff of 0.196. Sample sizes of 
137 (152) per placebo and 137 (152) per drug group were sufficient in order to yield 80% 
power for serial MoCA (or MMSE assessments). By contrast, if instead unselected patients 
with PD were enrolled to test the same experimental drug (over the same time period, 
assuming the same α, same standard deviation, and same test-retest correlations), 801 (802) 
patients would need be enrolled for each of the active treatment and placebo arms to achieve 
80% power for serial MoCA (or MMSE assessments) (figure 5C). Detailed methods and two 
illustrative case studies are shown in the appendix. Medications inhibiting acetylcholine 
esterase activity (AChE) can be used to enhance cognitive function in patients with PD and 
could conceivably inflate MMSE scores. However, we found no statistically significant 
influence of AChE inhibitors (rivastigmine, donepezil and galantamine) on MMSE scores in 
the three cohorts with pertinent medication information (PPMI, PDBP, HBS), neither at 
enrollment nor during longitudinal follow-up.
For longitudinal analyses, examining the performance and stability of the prediction 
accuracy for various time frames (not just the ten-year time frame) using time-dependent 
ROC curves is of interest. For our score, the time-dependent prediction accuracy (as 
measured by the incident/dynamic average iAUC24) was stable at various time points (from 
1 to 11 years from disease onset; appendix figure 4). It somewhat degraded during year 12, 
likely due to the relatively low number of patients who completed 12 years of follow-up.
Collectively, the clinical-genetic cognitive predictive score was robustly associated with both 
binary and continuous longitudinal cognitive outcomes, including global cognitive 
impairment, level 1 dementia, and decline in MMSE and MoCA scores over time.
A clinical variables-only version of the predictive score—In settings where GBA 
genotyping is not easily obtained, a version of the score comprising only the six clinical 
features (without GBA) could be used. This clinical score was informative and predicted 
global cognitive decline with high accuracy in both the discovery population with an AUC of 
0.859 (95% CI, 0.816 – 0.898) and the validation population with an AUC of 0.827 (95% CI, 
0.741 – 0.893) (appendix figure 5A, B). However, in a head-to-head comparison with the 
clinical-genetic score, the prediction accuracy of the clinical-only score significantly 
underperformed (p < 0.0001; appendix figure 5E).
Discussion
We have developed and replicated a cognitive risk score in 2,830 patients with PD and 
25,069 longitudinal clinical assessments. The area under the curve for accurately predicting 
global cognitive impairment within ten years of disease onset was greater than 85% in both 
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the discovery and validation populations (with 95% CIs of 0.821–0.902 and 0.779 – 0.913, 
respectively). The AUC for predicting development of dementia within ten years from 
disease onset was 87.7% (95% CI, 0.788 – 0.943) in the validation population. The cognitive 
risk score was associated with the binary outcomes of future cognitive impairment and 
dementia as well as continuous longitudinal measures such as a steeper decline in MMSE 
and MoCA scores tracked over time.
In addition to the clinical-genetic risk factors here evaluated, reduced levels of Aβ42 in 
cerebrospinal fluid have been linked to dementia in PD25 and this is supported by 
neuroimaging studies with Amyloid PET26. The predictive score is non-invasive, without the 
risks associated with lumbar puncture and without the restricted availability of PET imaging. 
The clinical-genetic version can be implemented in any setting with access to a certified 
gene testing lab. The clinical variables-only version can be nearly universally deployed.
The prediction algorithm developed has strengths. It was built starting from a small set of 
variables linked to cognitive decline or dementia in PD by prior evidence. This enhances the 
validity of the variables in the score. The parameters were winnowed down through machine 
learning. The predictor was built (as well as tested) in longitudinal cohorts, a superior study 
design compared to time-static, cross-sectional studies. The cohorts included vary in their 
design, recruitment, and assessments. PICNICS, CamPaIGN, and PROPARK are 
population-based cohorts designed to represent a community. HBS, PDBP, and PPMI are 
biomarkers cohorts. DATATOP and PreCEPT are clinical trial cohorts. These cohorts are not 
representative of the PD patient population as a whole, however, they are similar to “typical” 
clinical trial populations in the US. The fact that the score was informative across these 
varying cohorts is a testament to its robustness. It should be usable for other similar cohorts 
and most importantly, trial populations.
The score has the potential to facilitate clinical trials of experimental treatments designed to 
ameliorate or slow cognitive decline. Therapeutic trials in PD are hampered by the highly 
varied rate of progression to clinical endpoints. Because some participants with PD on 
placebo will experience minimal decline in cognition, it is difficult to demonstrate a 
therapeutic effect of the experimental therapeutic over a reasonable sample size and time 
course. The prognostic score represents a simple tool for stratifying and enriching the trial 
with patients most prone to rapid cognitive decline. Therapeutics that arrest or slow down 
the cognitive decline leading to dementia (which can be taken as a surrogate marker of 
advancing pathology) are likely to be disease modifying. Our power analysis estimated that 
recruiting patients with high cognitive risk scores >0.196 into such a trial will reduce the 
required samples size by as much as 6-fold (figure 5C). Our model should translate into 
more cost-effective trials, allow for “more shots on target”, and increase chances of success.
Our cognitive predictive score yields substantial negative predictive values of 88.4% for 
cognitive impairment and 92.0% for dementia within ten years from disease onset, but it is 
not yet ready for use in routine clinical care. A necessary next step towards use in clinical 
care will be a large prospective study using a neuropsychological test battery. If further 
confirmed, a low score could be reassuring for some patients and their families and inform 
planning decisions. On the other hand, a high score, while beneficial for enriching a research 
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trial population, has a limited positive predictive value for a specific patient (in part due to 
the modest prevalence of cognitive impairment in the general PD population). It is as yet 
unknown, whether modification of any of the risk factors comprising the score will impact 
on cognitive outcome. This raises difficult ethical questions similar to issues surrounding 
ApoE4 testing in mild cognitive impairment27. Education is per definition modifiable, but no 
ready made interventions have been delineated for PD. Trials of GBA-directed therapeutics 
are just beginning. As with any medical advance pushing beyond current practice paradigms, 
the appropriate medical and ethical framework for considering the cognitive predictive score 
in practice settings will have to be carefully outlined.
In the DATATOP and PreCEPT cohorts, DNA was collected several years after enrollment 
for a subset of participants9. They may underrepresent patients with more rapidly 
progressive disease, but it is unlikely that this would yield a spurious association between 
the cognitive predictive score and cognitive decline. The Cochran’s Q-test for heterogeneity 
of effects across cohorts indicated that any differences in disease progression between 
studies (due to sampling or selection effects) should not bias the test. We found no evidence 
that memory enhancing medications or drop outs materially influenced the results of this 
study.
The frequency of global cognitive impairment (within ten years from disease onset) among 
patients with PD in the discovery and validation populations was consistent, 24.7% and 
26.0%, respectively, based on Kaplan-Meier estimates. These estimates are in keeping with 
reported prevalence estimates, ranging from 18.9%28 to 57.1% for mild cognitive 
impairment29 and from 8.3% to 41% for dementia among patients with PD (reviewed in23). 
Furthermore, natural history studies have attempted to capture the frequency of cognitive 
impairment in PD, but due to major design differences, the range of estimates is wide, from 
26%2 to as high as 83% among twenty-year survivors30. A definite view has not crystallized 
due to small sample sizes, variable follow-up lengths, and fundamental differences in the 
analytical methods.
Going forward, we plan to refine the score and extend its applications. Ongoing efforts to 
map the genomes and epigenomes of Parkinson’s patients should discover new predictors. 
Such data can, in theory, be seamlessly integrated into the versatile prediction tool we have 
here developed. We believe that in the near future, data-driven prediction will inspire a new 
proactive and preventive approach to PD.
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Evidence before this study
We searched PubMed with the terms “Parkinson’s disease”, “dementia”, “cognitive 
impairment” for reports published before October, 2015. Previous studies identified 
individual clinical risk factors associated with cognitive deficits in PD. Recently, 
mutations in the Gaucher’s disease-associated gene β-glucocerebrosidase (GBA) were 
associated with cognitive impairment in PD. The user-friendly Framingham 
Cardiovascular Risk score estimates a patient’s 10-year risk of having a heart attack 
based on age, gender, and cardiovascular risk factors and has had a major impact on 
medical practice. For PD, however, no integrated and widely applicable assessment tool 
for predicting the risk of cognitive decline is available.
Added value of this study
We built and validated a first clinical-genetic score for the prediction of cognitive decline 
in patients with PD. This cognitive risk score accurately predicted cognitive impairment 
within ten years of disease onset with an area under the curve (AUC) of >0.85. The 
predictive score may be of particular use for enriching clinical trials designed for disease 
modification, for preventing or ameliorating cognitive decline. The sample size required 
for such a hypothetical trial could be reduced by as much as 6-fold, if only high risk 
patients are included, compared with an equally powered trial of “all comers”. A beta-
version of the cognitive risk calculator is available online.
Implications of all the available evidence
The score will enable trialists to enrich their populations with participants most likely to 
experience cognitive decline. Further studies are needed to identify and validate 
additional clinical, genetic, and biological risk factors that could be seamlessly integrated 
into this versatile risk assessment tool.
Liu et al. Page 14













Figure 1. Flow chart of study design
HBS=Harvard Biomarkers Study, DATATOP=Deprenyl and Tocopherol Antioxidative 
Therapy of Parkinsonism; PreCEPT=Parkinson Research Examination of CEP-1347 Trial/A 
Longitudinal Followup of the PRECEPT Study Cohort; CamPaIGN=Cambridgeshire 
Parkinson’s Incidence from GP to Neurologist; PICNICS=Parkinsonism Incidence, 
Cognition and Non-motor heterogeneity in Cambridgeshire; DIGPD=Drug Interaction with 
Genes in PD; PROPARK=PROfiling PARKinson’s disease study; PDBP=Parkinson’s 
Disease Biomarkers Program; PPMI=Parkinson’s Progression Marker Initiative (PPMI). 
AUC=area under the curve.
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Figure 2. Prediction of global cognitive impairment
(A,B) The cognitive risk score showed high accuracy (quantified by AUC estimates) for 
predicting, whether a patient will develop global cognitive impairment within ten years from 
disease onset in the discovery and the validation populations. (A) In the discovery 
population, 1,350 patients with PD and MMSE > 25 at baseline were followed with 5,165 
visits for up to 12.8 (median, 2.8) years. (B) In the independent validation population, 1,132 
patients with PD and MMSE > 25 at baseline were followed with 19,127 visits for up to 8.6 
(median, 6.5) years. Sensitivity and specificity at the cutoff score of 0.196 (the optimal 
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cutoff identified in the discovery population) are shown for both populations. (C,D) 
Covariate-adjusted Kaplan-Meier curves for survival free of global cognitive impairment. 
(C) In the discovery population, 95.8% (95% CI 92.7%–99.1%) of patients with PD in the 
lowest (first) quartile of scores survived for ten years without global cognitive impairment 
compared to 34.9% (95% CI 26.5%–46.2%) of those scoring in the highest (fourth) quartile. 
(D) In the validation population, 96.3% (95% CI 94.1% – 98.6%) of patients in the lowest 
quartile of scores survived for ten years without global cognitive impairment compared to 
27.4% (95% CI 12.6%–59.8%) of patients scoring in the highest quartile scores. To ensure 
consistency across studies, an MMSE score with the cutoff of ≤ 25 was taken as an indicator 
of significant global cognitive impairment as recommended by the International Parkinson 
and Movement Disorders Society (MDS) Task Force17.
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Figure 3. Prediction of dementia
Beyond cognitive decline, the clinical-genetic score predicts risk of dementia in individuals 
with PD in validation population. 1,132 patients (without global cognitive impairment at 
baseline) with 19,127 longitudinal study visits were available for this analysis. The accuracy 
of the clinical-genetic score for predicting dementia was high with an AUC of 0.877 (95% 
CI 0.788–0.943). Sensitivity and specificity for predicting dementia at the cutoff (0.196; as 
predefined in the discovery population).
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Figure 4. Stability of the score
To test the stability of the predictive score, we rebuilt and retested the score model in 10,000 
randomly generated training and test subsets. In each iteration the entire population of 
patients was randomly split into a training and a test set pair. In each iteration, we rebuilt the 
predictive score ab initio in the training set, eliminated predictor variables based on the 
Akaike information criterion, and used it to predict global cognitive decline in the 
corresponding test set. (A) In 10,000 iterations, age at onset, enrollment MMSE score, and 
years of education remained in the score model after stepwise pruning in 100% of iterations, 
enrollment MDS-UPDRS III in 98.30%, GBA carrier status in 91.79%, depression in 
90.61%, and gender in 78.52%. HY stage (which did not make it into our clinical-genetic 
score) was included in 34.86% of iterations. (B) Across the 10,000 re-sampled test sets, the 
mean AUC was 0.833 (95% CI, 0.785–0.876) for predicting global cognitive impairment 
and, even higher, 0.872 (95% CI, 0.817–0.929) for dementia. These data indicate stable 
variable selection and score performance.
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Figure 5. Prediction of longitudinal trajectories of Mini Mental State Exam (MMSE) and 
Montreal Cognitive Assessment (MoCA) scores
(A) To evaluate longitudinal trajectories of serial MMSE scores in the patients with high (> 
0.196) vs. low enrollment cognitive predictive scores (≤ 0.196) at enrollment, we performed 
a generalized mixed random and fixed effects longitudinal meta-analysis adjusting for 
disease duration at enrollment. These analyses were conservatively restricted to the 
validation population. PD patients with high enrollment predictive scores had a significantly 
more rapid longitudinal decline in MMSE scores over time with p < 0.0001 compared to the 
patients with low enrollment predictive scores. Illustrative mean MMSE scores across time 
predicted from the estimated fixed effect parameters in the mixed random and fixed effects 
model analysis are shown for Parkinson’s patients with low clinical-genetic predictive scores 
(blue) and those with high scores at enrollment (red). Patients with high scores (measured at 
enrollment) had a more rapid decline in cognitive function (as measured by serial MMSE) 
compared to those with low scores with p < 0.0001 adjusting for duration of PD at 
enrollment. Illustrative MMSE values for a mean disease duration at enrollment are shown. 
CRS=global cognitive impairment predictive score.
(B) Illustrative mean MoCA scores across time predicted from the estimated fixed effect 
parameters in the mixed random and fixed effects model analysis in Parkinson’s patients 
with low clinical-genetic predictive scores (≤ 0.196; blue) and those with high scores at 
enrollment (> 0.196; red). Patients with high clinical-genetic scores at enrollment had a 
more rapid decline in MoCA scores compared to those with low scores with p < 0.0001 
adjusting for disease duration at enrollment. The analysis of MoCA scores was restricted to 
PPMI and PreCEPT, the two validation cohorts, which had included this scale into their 
assessment battery. MoCA scores were not collected in DATATOP. Illustrative MoCA values 
for a mean disease duration at enrollment are shown.
(C) Improved power for clinical trials in populations with elevated clinical-genetic scores. 
Enriching populations based on the clinical-genetic score >0.196 for trials of therapeutics 
designed to address cognitive impairment in PD will reduce the required sample size by 6-
fold compared to an equally powered trial without enrichment. In this hypothetical power 
estimate, required sample sizes were 137 for the placebo and 137 for the experimental 
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treatment group in order to achieve 80% power. A traditional clinical trial of any PD patients 
(not enriched based on the clinical-genetic score) would require 801 patients per group to 
achieve the same power (over the same three-year time period, assuming same α, standard 
deviation, and test-retest correlations). α= 0.05 for detecting the difference in trajectories for 
MoCA across time for the placebo vs. the treatment group (group × time interaction).
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Table 2
Patients with high cognitive predictive scores have a substantially increased hazard ratio for global cognitive 
impairment compared to those with scores in the lowest quartile.
Quartile
1 2 3 4
0 to <0.0954 0.0954 to <0.1958 0.1958 to <0.3789 0.3789 to ≤1
Discovery population
Parkinson’s disease (N) 338 337 337 338
Cognitive predictive scores (range) 0.0076–0.0954 0.0954–0.1955 0.1961–0.3788 0.3789–1.0000
HR (95% CI)# 1 2.7 (1.2–5.9) 6.0 (2.9–12.5) 21.6 (10.9–42.9)
p value 0.013 <0.0001 <0.0001
Validation population
Parkinson’s disease (N) 375 320 281 156
Cognitive predictive scores (range) 0.0089–0.0951 0.0955–0.1951 0.1959–0.3776 0.3809–0.9729
HR (95% CI)# 1 3.2 (1.6–6.7) 8.3 (4.2–16.2) 18.4 (9.4–36.1)
p value 0.0015 <0.0001 <0.0001
#
Hazard ratio (HR) and confidence intervals (CI) were calculated using Cox regression models.
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Table 3
Patients with high cognitive predictive scores have an increased hazard ratio for dementia compared to those 
with scores in the lowest quartile.
Quartile
1 2 3 4
0 to <0.0954 0.0954 to <0.1958 0.1958 to <0.3789 0.3789 to ≤1
Validation population
Parkinson’s disease (N) 372 317 279 154
Cognitive predictive scores (range) 0.0089–0.0951 0.0955–0.1951 0.1959–0.3376 0.3809–0.9729
HR (95% CI)# 1 3.1 (0.8–11.9) 8.8 (2.6–30.0) 21.9 (6.5–73.1)
p value 0.091 0.0005 <0.0001
#
Hazard ratio (HR) and confidence intervals (CI) were calculated using Cox regression models.
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